Design of a modular immunotoxin connected by polyionic adapter peptides

被引:12
作者
Kleinschmidt, M [1 ]
Rudolph, R [1 ]
Lilie, H [1 ]
机构
[1] Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle An Der Saale, Germany
关键词
Fv fragment; exotoxin; disulfide bond; polyionic peptides; FACS;
D O I
10.1016/S0022-2836(03)00141-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotoxins are genetically engineered fusion proteins of an antibody Fv fragment and a toxin from bacteria or plants, which function as anticancer therapeutics. Here, we describe a new generation of immunotoxins in which both proteins do not form a single fusion protein but are coupled specifically via cysteine-containing polyionic fusion peptides. The engineered Pseudomonas exotoxin PE38 was N-terminally fused to the peptide E8C. In combination with the disulfide-stabilized Fv fragment of the tumor-specific antibody B3, which was extended by the peptide R8CP, the fusion peptides ensured a specific and covalent coupling of the Fv fragment and the toxin. The resulting immunotoxin was as active and as specific as an immunotoxin consisting of a fusion protein of the same antibody fragment connected to the toxin. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:445 / 452
页数:8
相关论文
共 41 条
[1]   A fluorescence investigation of the active site of Pseudomonas aeruginosa exotoxin A [J].
Beattie, BK ;
Merrill, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (22) :15646-15654
[2]   In vitro enzyme activation and folded stability of Pseudomonas aeruginosa exotoxin A and its C-terminal peptide [J].
Beattie, BK ;
Merrill, AR .
BIOCHEMISTRY, 1996, 35 (28) :9042-9051
[3]   A RECOMBINANT IMMUNOTOXIN CONTAINING A DISULFIDE-STABILIZED FV FRAGMENT [J].
BRINKMANN, U ;
REITER, Y ;
JUNG, SH ;
LEE, B ;
PASTAN, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (16) :7538-7542
[4]   Recombinant immunotoxins for cancer therapy [J].
Brinkmann, U ;
Keppler-Hafkemeyer, A ;
Hafkemeyer, P .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (04) :693-702
[5]  
CARMICHAEL J, 1987, CANCER RES, V47, P943
[6]  
CARR DW, 1991, J BIOL CHEM, V266, P14188
[7]   Improving the efficacy of antibody-based cancer therapies [J].
Carter, P .
NATURE REVIEWS CANCER, 2001, 1 (02) :118-129
[8]   A GENERAL-METHOD FOR FACILITATING HETERODIMERIC PAIRING BETWEEN 2 PROTEINS - APPLICATION TO EXPRESSION OF ALPHA-T-CELL AND BETA-T-CELL RECEPTOR EXTRACELLULAR SEGMENTS [J].
CHANG, HC ;
BAO, ZZ ;
YAO, Y ;
TSE, AGD ;
GOYARTS, EC ;
MADSEN, M ;
KAWASAKI, E ;
BRAUER, PP ;
SACCHETTINI, JC ;
NATHENSON, SG ;
REINHERZ, EL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (24) :11408-11412
[9]   A RECOMBINANT IMMUNOTOXIN CONSISTING OF 2 ANTIBODY VARIABLE DOMAINS FUSED TO PSEUDOMONAS EXOTOXIN [J].
CHAUDHARY, VK ;
QUEEN, C ;
JUNGHANS, RP ;
WALDMANN, TA ;
FITZGERALD, DJ ;
PASTAN, I .
NATURE, 1989, 339 (6223) :394-397
[10]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648